Literature DB >> 18655914

Mammalian target of rapamycin as a target in hematological malignancies.

Isam A Abdel-Karim1, Francis J Giles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18655914     DOI： 10.1016/j.currproblcancer.2008.05.001

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  5 in total

1.  Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.

Authors:  Yang Liu; Srilakshmi Pandeswara; Vinh Dao; Álvaro Padrón; Justin M Drerup; Shunhua Lao; Aijie Liu; Vincent Hurez; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-10-13       Impact factor: 12.701

2.  Inhibition of human T-cell proliferation by mammalian target of rapamycin (mTOR) antagonists requires noncoding RNA growth-arrest-specific transcript 5 (GAS5).

Authors:  Mirna Mourtada-Maarabouni; Anwar M Hasan; Farzin Farzaneh; Gwyn T Williams
Journal:  Mol Pharmacol       Date:  2010-04-26       Impact factor: 4.436

Review 3.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

4.  The effect of rapamycin on bone growth in rabbits.

Authors:  Chanika Phornphutkul; Mark Lee; Cliff Voigt; Ke-Ying Wu; Michael G Ehrlich; Philip A Gruppuso; Qian Chen
Journal:  J Orthop Res       Date:  2009-09       Impact factor: 3.494

5.  Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.

Authors:  David T Teachey; Robert Greiner; Alix Seif; Edward Attiyeh; Jack Bleesing; John Choi; Catherine Manno; Eric Rappaport; Dirk Schwabe; Cecilia Sheen; Kathleen E Sullivan; Hongming Zhuang; Daniel S Wechsler; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-02-04       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.